London, UK / Amsterdam, The Netherlands / New York, US — 17 November 2025

Radcliffe Group today announced a significant step in its global expansion with the establishment of Radcliffe Medical Education (RME) B.V. in the Netherlands – its new global medical education head office – and Radcliffe Medical Education LLC in the United States. These developments mark an important milestone in the organisation’s ambition to strengthen its international presence and enhance its ability to support the global healthcare community.

The decision to expand into both regions reflects the rapid growth of Radcliffe’s client base and the increasing demand for high-quality, independent medical education across Europe, North America and worldwide. Relocating its primary medical education operations to the Netherlands positions Radcliffe to work more closely with EU-based pharmaceutical and MedTech partners, providing seamless access to the EU single market for IME/CME collaboration, contracting, grant funding, regulatory compliance and talent recruitment.

Simultaneously, the launch of RME LLC in the United States strengthens Radcliffe’s capacity to partner with leading American medical societies, academic institutions and industry organisations, supporting the company’s expanding educational programmes at major US congresses and its commitment to delivering locally relevant, globally accessible scientific learning.

On the move, David Ramsey, CEO of Radcliffe Group, commented, “This dual expansion into the Netherlands and the United States represents a transformational moment for Radcliffe. As demand for international collaboration in medical education accelerates, we are building the infrastructure necessary to better support clinicians, industry partners and academic stakeholders around the world. These new entities allow us to work more effectively across key markets and help improve patient outcomes by advancing scientific knowledge and professional learning.”
 

The Netherlands provides a strategic hub for European operations, benefitting from world-class life-science institutions, leading medical research centres and exceptional transport access to major global congresses. The United States remains the largest and most influential market for medical education and scientific innovation, and Radcliffe’s expanded presence there enables deeper engagement with clinical experts and commercial partners across cardiovascular and related disciplines.

The organisation will implement a phased operational transition while maintaining its UK footprint and ensuring continuity of service for all existing partners.